Εμφάνιση απλής εγγραφής

dc.creatorKyriakis E., Karra A.G., Papaioannou O., Solovou T., Skamnaki V.T., Liggri P.G.V., Zographos S.E., Szennyes E., Bokor É., Kun S., Psarra A.-M.G., Somsák L., Leonidas D.D.en
dc.date.accessioned2023-01-31T08:47:40Z
dc.date.available2023-01-31T08:47:40Z
dc.date.issued2020
dc.identifier10.1016/j.bmc.2019.115196
dc.identifier.issn09680896
dc.identifier.urihttp://hdl.handle.net/11615/75572
dc.description.abstractC-Glucopyranosyl imidazoles, thiazoles, and an N-glucopyranosyl tetrazole were assessed in vitro and ex vivo for their inhibitory efficiency against isoforms of glycogen phosphorylase (GP; a validated pharmacological target for the development of anti-hyperglycaemic agents). Imidazoles proved to be more potent inhibitors than the corresponding thiazoles or the tetrazole. The most potent derivative has a 2-naphthyl substituent, a Ki value of 3.2 µM for hepatic glycogen phosphorylase, displaying also 60% inhibition of GP activity in HepG2 cells, compared to control vehicle treated cells, at 100 μM. X-Ray crystallography studies of the protein – inhibitor complexes revealed the importance of the architecture of inhibitor associated hydrogen bonds or sulfur σ-hole bond interactions to Asn284 OD1, offering new insights to structure-based design efforts. Moreover, while the 2-glucopyranosyl-tetrazole seems to bind differently from the corresponding 1,2,3-triazole compound, the two inhibitors are equipotent. © 2019 Elsevier Ltden
dc.language.isoenen
dc.sourceBioorganic and Medicinal Chemistryen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85076026403&doi=10.1016%2fj.bmc.2019.115196&partnerID=40&md5=35b2a3588f3b971c8cb05e27585c4267
dc.subject1,2,3 triazole derivativeen
dc.subjectc beta dextro glucopyranosyl thiazole derivativeen
dc.subjectglycogen phosphorylaseen
dc.subjecthydrogenen
dc.subjecthyperglycemic agenten
dc.subjectimidazole derivativeen
dc.subjectn beta dextro glucopyranosyl tetrazoleen
dc.subjectthiazole derivativeen
dc.subjectunclassified drugen
dc.subjectenzyme inhibitoren
dc.subjectglycogen phosphorylaseen
dc.subjecthydrogenen
dc.subjectimidazole derivativeen
dc.subjectsulfuren
dc.subjecttetrazole derivativeen
dc.subjectthiazole derivativeen
dc.subjectArticleen
dc.subjectcontrolled studyen
dc.subjectdrug designen
dc.subjectdrug potencyen
dc.subjectdrug structureen
dc.subjectdrug synthesisen
dc.subjectdrug targetingen
dc.subjectenzyme activityen
dc.subjectenzyme inhibitionen
dc.subjectenzyme inhibitor complexen
dc.subjectex vivo studyen
dc.subjectHep-G2 cell lineen
dc.subjecthumanen
dc.subjecthuman cellen
dc.subjecthydrogen bonden
dc.subjectin vitro studyen
dc.subjectX ray crystallographyen
dc.subjectchemical structureen
dc.subjectchemistryen
dc.subjectdose responseen
dc.subjectmetabolismen
dc.subjectmolecular modelen
dc.subjectstructure activity relationen
dc.subjectsynthesisen
dc.subjectCrystallography, X-Rayen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Designen
dc.subjectEnzyme Inhibitorsen
dc.subjectGlycogen Phosphorylase, Liver Formen
dc.subjectHep G2 Cellsen
dc.subjectHumansen
dc.subjectHydrogenen
dc.subjectImidazolesen
dc.subjectModels, Molecularen
dc.subjectMolecular Structureen
dc.subjectStructure-Activity Relationshipen
dc.subjectSulfuren
dc.subjectTetrazolesen
dc.subjectThiazolesen
dc.subjectElsevier Ltden
dc.titleThe architecture of hydrogen and sulfur σ-hole interactions explain differences in the inhibitory potency of C-β-D-glucopyranosyl thiazoles, imidazoles and an N-β-D glucopyranosyl tetrazole for human liver glycogen phosphorylase and offer new insights to structure-based designen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής